Comments
The shares of Dr Reddy's Laboratories surged as much as 8.7 per cent to ₹2,655 on Wednesday, their highest since Sept. 26.
A U.S. appeals court on Tuesday allowed the generic drugmaker to sell a copycat version of its rival Indivior Plc's opioid treatment Suboxone Film. The court has also lifted a preliminary injunction filed by UK-based Indivior that blocked Dr. Reddy's from selling the generic drug.
This ruling is a near-term positive and allows re-launch and reduces risk on ongoing patent case, Jefferies says in a note. It also retains “underperform” rating with a price target of ₹2,100.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.